Medtronic Plc's stock has seen fluctuations, outperforming competitors on some days and underperforming on others. Its third quarter of fiscal 2024 showed strong financial results, but investors expressed concerns over
Medtronic's weak financials and whether they could impede momentum. This concern is fueled by a decline of about 23% in
Medtronic’s shares over the past three years. In contrast, data from the
MiniMed 780G System was positively received.
Medtronic's Chief Financial Officer, Karen Parkhill, will be leaving the company, and the firm's Q4 earnings beat estimates despite margins declining.
Medtronic also raised its FY24 guidance on strong Q3 results and announced a cash dividend for the fourth quarter of fiscal year 2024. The company received FDA approval for the newest-generation
Evolut TAVR system for symptomatic severe aortic stenosis treatment and announced the closing of a public offering of €3.0 billion of senior notes.
Medtronic Plc MDT News Analytics from Tue, 22 Aug 2023 07:00:00 GMT to Sun, 07 Jul 2024 08:49:33 GMT -
Rating 4
- Innovation -3
- Information 7
- Rumor -6
